Differential benefit from fractionated dose-dense first-line chemotherapy for epithelial ovarian cancer (EOC) according to KELIM-evaluated tumor primary chemosensitivity: Exploratory analyses of ...
EO1001 Phase 1-2a study featured at ASCO 2026; dose escalation successfully completed and Phase 2 expansion cohorts actively enrolling at biologically active dose levels EO1001 is specifically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results